Shares of Bayer AG (FRA:BAYN) have been assigned an average recommendation of “Buy” from the twenty-two research firms that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and fourteen have issued a buy recommendation on the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is €121.80 ($145.00).
A number of research analysts recently commented on the stock. Baader Bank set a €140.00 ($166.67) price objective on shares of Bayer and gave the company a “buy” rating in a research report on Thursday. DZ Bank reaffirmed a “buy” rating on shares of Bayer in a research report on Monday, December 11th. set a €105.00 ($125.00) price objective on shares of Bayer and gave the company a “neutral” rating in a research report on Wednesday, August 23rd. Independent Research set a €120.00 ($142.86) price objective on shares of Bayer and gave the company a “neutral” rating in a research report on Wednesday, September 13th. Finally, Commerzbank set a €124.00 ($147.62) price objective on shares of Bayer and gave the company a “buy” rating in a research report on Friday, September 15th.
Shares of Bayer (FRA:BAYN) traded up €1.30 ($1.55) on Friday, reaching €107.80 ($128.33). 2,457,143 shares of the company were exchanged. Bayer has a 52-week low of €95.95 ($114.23) and a 52-week high of €123.82 ($147.40).
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and womens health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
What are top analysts saying about Bayer? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Bayer and related companies.